title: Tendon disorders attributed to fluoroquinolones: a study on 42 spontaneous reports in the period 1988 to 1998.
abstract: OBJECTIVE
  Fluoroquinolone antibiotics have been associated with tendinitis and tendon rupture. In this paper we report on the followup of 42 spontaneous reports of fluoroquinolone-associated tendon disorders.
  
  
  METHODS
  This study is based on cases of fluoroquinolone-associated tendon disorders reported to the Netherlands Pharmacovigilance Foundation Lareb and the Drug Safety Unit of the Inspectorate for Health Care between January 1, 1988, and January 1, 1998. By means of a mailed questionnaire, we collected information on the site of injury, onset of symptoms, treatment, and course of the tendon disorder as well as information on possible risk factors and concomitant medication.
  
  
  RESULTS
  Of 50 mailed questionnaires, 42 (84%) were returned. The data concerned 32 patients (76%) with tendinitis and 10 patients (24%) with a tendon rupture. Sixteen cases (38%) were attributed to ofloxacin, 13 (31%) to ciprofloxacin, 8 (19%) to norfloxacin, and 5 (12%) to pefloxacin. There was a male predominance, and the median age of the patients was 68 years. Most of the reports concerned the Achilles tendon, and 24 patients (57%) had bilateral tendinitis. The latency period between the start of treatment and the appearance of the first symptoms ranged from 1 to 510 days with a median of 6 days. Most patients recovered within 2 months after cessation of therapy, but 26% had not yet recovered at followup.
  
  
  CONCLUSIONS
  These reports suggest that fluoroquinolone-associated tendon disorders are more common in patients over 60 years of age. Ofloxacin was implicated most frequently relative to the number of filled prescriptions in the Netherlands.
authors.affiliation: Department of Epidemiology & Biostatistics, Erasmus Medical Center, Rotterdam, The Netherlands.
authors.forename: P D
authors.initials: PD
authors.lastname: van der Linden
authors.forename: E P
authors.initials: EP
authors.lastname: van Puijenbroek
authors.forename: J
authors.initials: J
authors.lastname: Feenstra
authors.forename: B A
authors.initials: BA
authors.lastname: Veld
authors.forename: M C
authors.initials: MC
authors.lastname: Sturkenboom
authors.forename: R M
authors.initials: RM
authors.lastname: Herings
authors.forename: H G
authors.initials: HG
authors.lastname: Leufkens
authors.forename: B H
authors.initials: BH
authors.lastname: Stricker
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D008875:Middle Aged; D011795:Surveys and Questionnaires; D052256:Tendinopathy / Q000139:chemically induced* / Q000503:physiopathology; D013708:Tendon Injuries / Q000139:chemically induced*
chemical_list: D000890:Anti-Infective Agents; D024841:Fluoroquinolones